LorettaLMuellerDOFACOFP

Research History

• Principal Investigator"Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended-Release for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial” Cephalon Pharmaceuticals, Investigator-Initiated2010 - 2013
• Principal Investigator"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders" Merck & Co., Inc2009 - 2010
• Principal Investigator“The Evolution and Management of Migraine Recurrence Beyond 24 Hours: A Prospective Study of Tertiary Care Center Patients” Endo Pharmaceuticals (Investigator Initiated)2008 - 2009
• Principal Investigator“A Phase IIa, Multicenter, Randomized, Placebo-Controlled Cinical Trial to Study the Safety and Efficacy of Telcagepant (MK-9074) for Migraine Prophylaxis in Patients with Episodic Migraine” Merck & Co., Inc2008 - 2009
• Principal Investigator“A RDBPC, Double-Dummy, Crossover Study to Evaluate the Efficacy of TREXIMA (Sumatriptan and Naproxen Sodium) versus Butalbital-Containing Combination Medications for the Acute TX of Migraine when Administered during the Mod-Severe Pain Phase of the Migraine” TRX109011 GlaxoSmithKline2008 - 2008
• Principal Investigator“A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 with Placebo for the Acute Treatment of Migraine With or Without Aura” #031 Merck and Co, Inc2008 - 2008
• Principal Investigator“A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response of Intolerance to Eletriptan (Study 2 of 2)” TRX106573 GlaxoSmithKline2006 - 2007
• Principal Investigator"A RDB, Single Migraine Attack, Placebo-Controlled, Parallel-Group Multicenter Study to Evaluate the Efficacy and Tolerability of Treximet Tablets vs Placebo when Administered During the Mild Pain Phase of Menstrual Migraine in Women with Dysmenorrhea” TRX105850 GlaxoSmithKline2006 - 2006
• Principal Investigator" A RDBPC, Multi-Center, Cross-Over Study to Determine the Consistency of Treximet (Sumatriptan 85mg/Naproxen Sodium 500mg) in the Acute Treatment of Multiple Migraine Attacks” TRX103635 GlaxoSmithKline2005 - 2006
• Co-Investigator“Medical Informatics in Headache Management and its Long Term Effects on Diagnosis and Treatment of Headaches” National Headache Foundation, Investigator Initiated2005 - 2005
• Principal Investigator“A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Tablet for the Treatment of Menstrual Migraine" Protocol #071-00 and 072-00 Merck & Co., Inc2005 - 2005
• Principal Investigator"A RDBPC, Parallel Group, Single-Attack Evaluation of the Efficacy and Tolerability of Treximet (sumatriptan 85mg/naproxen sodium 500mg) Tablets vs. Placebo When Administered During the Mild Phase of a Migraine” Protocol #101998 GlaxoSmithKline2004 - 2005
• Principal Investigator“A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10mg Tablet Administered Early During a Migraine Attack While the Pain is Mild” Protocol #065-00 Merck & Co., Inc.2004 - 2005
• Principal Investigator“A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10mg Tablet Administered Early During a Migraine Attack While the Pain is Mild” Protocol #066-00 Merck & Co., Inc.2004 - 2005
• Principal Investigator"A DBPC, Parallel Group Study with an Open-Label Extension Phase to Assess the Efficacy, Tolerability, and Safety of Oral Frovatriptan in the Prevention of Menstrually-Related Migraine Migraines in a “Difficult to Treat” Population” Protocol #VML 251-3MRM02 Vernalis2004 - 2004
• Principal Investigator“A Comparison of the Efficacy and Safety of Ultracet (Tramadol HCL/Acetaminophen) versus Placebo for the Acute Treatment of Migraine Headache Pain” Ortho-McNeil2003 - 2004
• Principal Investigator"A RDBPC, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine” GlaxoSmithKline2003 - 2004
• Co-Investigator“A Phase II Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches” NPS Pharmaceuticals2003 - 2004
• Principal Investigator“Weight Gain Considerations in the Formulation of a Headache Treatment Regimen” Ortho-McNeil, Investigator-Initiated2003 - 2003
• Principal Investigator"A RDBPC, Parallel-Group Study to Evaluate the Efficacy and Tolerability of Oral Sumatriptan 25mg, 50mg, and 100mg for a Single Moderate or Severe Headache in Adults Diagnosed with Migrainous Disorder” GlaxoSmithKline2002 - 2003
• Principal Investigator“A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (Zomig) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine” AstraZeneca2002 - 2003
• Principal Investigator“A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (Zomig) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine” AstraZeneca2002 - 2003
• Principal Investigator“Family Medicine Residency Training in Headache Management and Its Long-Term Effects on Diagnosis and Treatment of Headaches” National Headache Foundation, Investigator Initiated2002 - 2002
• Co-Investigator"A Multi-Center, DBPC, Parallel-Group, Single-Dose Pilot Study Comparing the Efficacy and Safety of Excedrin Migraine with Sumatriptan Succinate in the Acute Treatment of Migraine Headache When Taken at the First Sign of Migraine” Bristol-Myers Squibb2002 - 2002
• Principal Investigator“A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Trial to Evaluate the Efficacy and Tolerability of the Zolmitriptan 5 mg. Orally Disintegrating Tablet in the Acute Treatment of Adult Subjects with Migraine” Astra Zeneca2001 - 2001
• Co-Investigator“A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine” Ortho-McNeil2001 - 2001
• Co-Investigator"A RDBPC, Three-Way Cross-Over Clinical Study to Assess the Safety and Efficacy of 2 Dose Regimens of Frovatriptan, Compared With Placebo, in Preventing Menstrually-Associated Migraine Headaches” Elan2001 - 2001
• Co-InvestigatorParallel Group, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Montelukast 20mg./day P.O. and Rofecoxib 25 mg./day P.O. for the Prophylaxis of Migraine Attacks” Merck & Co.2000 - 2000
• Principal Investigator“An Open-Label Evaluation of the Long-Term Safety of Oral Naratriptan 1 mg. Twice Daily as Short-Term Prophylactic Treatment for Menstrually-Associated Migraine” Glaxo Wellcome2000 - 2000
• Principal Investigator“Residency Preceptorship in Headache Management. A two-week structured preceptorship for Family Medicine Residents" Merck, Investigator-Initiated2000 - 2000
• Co-Investigator“Osteopathic Manipulative Therapy in the Treatment of Chronic Headache” American Osteopathic Association, Investigator-Initiated2000 - 2000
• Principal Investigator"A RDBPC, Parallel Group, Single Attack Evaluation of Sumatriptan 50 mg. and 100 mg. versus Placebo During a Migraine Headache at the First Sign of Pain” Glaxo Wellcome2000 - 2000
• Co-Investigator"Efficacy and Safety of the Combination Product Acetaminophen, Asprin and Caffeine Compared to Ibuprofen and to Placebo in the Acute Treatment of Migraine Attacks" Bristol-Myers Squibb PharmNet, Inc.1999 - 1999
• Principal Investigator"Efficacy and Safety of the Combination Product Acetaminophen, Asprin and Caffeine Compared to Ibuprofen and to Placebo in the Acute Treatment of Episodic Tension-Type Headaches" Bristol-Myers Squibb PharmNet, Inc.1999 - 1999
• Principal Investigator"A Randomized, Open-Label, Two-Period Crossover Study Comparing Preference for Rizatriptan MLT 10 mg. or Sumatriptan 50 mg. Tablet for the Acute Treatment of Migraine" Merck & Company, Inc.1999 - 1999
• Principal Investigator"Reduction of Pro-Inflammatory Substances in Menstrual Migraines Related to Zomig Therapy" Zeneca Pharmaceuticals, Investigator-Initiated1998 - 1999
• Co-Investigator"Comparative Study of Midrin and Sumatriptan Succinate in the Treatment of Mild to Moderate Migraine Headaches" (Phase IV) Carnrick Labs, Inc.1998 - 1998
• Co-Investigator"Establishment of Department of Family Medicine to Further Establish a Division of Educational Development and Research Department of Health & Human Resources" - Health Resources & Service Administration1997 - 1998
• Principal Investigator"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Oral Naratriptan (2.5mg) for the Treatment of Migraine in Subjects who do not Respond to Oral Sumatriptan (50 mg)" Phase III Glaxo Wellcome Inc.1997 - 1998
• Co-Investigator"A Multicenter, Double-Blind, Randomized Comparison of Zolmitriptan (311C90, Zomig) and Sumatriptan in the Acute Treatment of Multiple Migraine Headaches" (Phase III) - Zeneca Pharmaceutical1997 - 1997
• Co-Investigator"A Single-Dose, Double-Blind, Dose Ranging, Placebo-Controlled Safety and Efficacy Study of Various Doses of Naproxen Sodium and Metoclopramide in Subjects with Acute Migraine Headaches" (Phase II) - Pozen, Inc.1997 - 1997
• Principal Investigator"A Multicenter, Double-blind, Placebo-Controlled Randomized Trial of Zolmitriptan (Zomig) for the Treatment of Menstrual-Associated Migraine Headaches" Phase III Zeneca Pharmaceuticals1997 - 1997
• Principal Investigator"Urine Cytokine Levels in Episodic Cluster Headache Patients" National Headache Foundation Grant, Investigator-Initiated1997 - 1997
• Co-Investigator"A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Single Dose Odansetron 8mg and Single Dose Odansetron 16mg for the Treatment of Opioid-Induced Nausea and Emesis in Subjects Experiencing Acute Pain" (Phase III) Glaxo Wellcome Inc.1996 - 1997
• Principal Investigator"Two-Period Crossover Comparison of Rizatriptan (5 mg p.o. and 10 mg p.o.) to Sumatriptan (25 mg p.o. and 50 mg p.o.)" Phase III - Merck and Co. Inc.1996 - 1997
• Co-Investigator"Parallel Study Comparing the Analgesic Effects of the Combination of Ibuprofen plus Caffeine Relative to Ibuprofen Alone in Subjects with Acute Tension-Type Headaches" (Phase III) - Proctor-Gamble Company1995 - 1996
• Co-Investigator"Bromfenac Versus a Combination of Butalbital, Aspirin, and Caffeine in Patients with Tension-Type Headache" (Phase III) Wyeth-Ayerst Pharmaceuticals1995 - 1996
• Co-Investigator"Correlation of Myers Briggs Type Indicator and Migraine Headache" - National Headache Foundation Grant, Investigator-Initiated1995 - 1995
• Co-Investigator"Effectiveness and Safety of D.H.E. Nasal Spray 2mg. For the Acute Treatment of Migraine Headache With or Without Aura in Migraineur Families" (Phase III) Sandoz Pharmaceuticals1995 - 1995
• Co-Investigator"DHE-45 Nasal Spray in the Treatment of Acute Migraine Headache" (Phase III) - Sandoz Pharmaceuticals1993 - 1994
• Co-Investigator"Role of Diet in Controlled Migraine Headache Patients" National Headache Foundation Grant, Investigator-Initiated1993 - 1993